Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study.
Khanna D, de Vries-Bouwstra J, Hoffmann-Vold AM, Kuwana M, Low AHL, Proudman S, Flack M, Kukreja A, Fagan N, Distler O. Khanna D, et al. J Scleroderma Relat Disord. 2024 Nov 7:23971983241291923. doi: 10.1177/23971983241291923. Online ahead of print. J Scleroderma Relat Disord. 2024. PMID: 39544899 Free PMC article.
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine.
Lescoat A, Bellando-Randone S, Campochiaro C, Del Galdo F, Denton CP, Farrington S, Galetti I, Khanna D, Kuwana M, Truchetet ME, Allanore Y, Matucci-Cerinic M. Lescoat A, et al. Among authors: khanna d. Lancet Rheumatol. 2023 Nov;5(11):e683-e694. doi: 10.1016/S2665-9913(23)00212-6. Epub 2023 Sep 26. Lancet Rheumatol. 2023. PMID: 38251534 Review.
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group; Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Scleroderma Research Group. Ferdowsi N, et al. Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30. Ann Rheum Dis. 2019. PMID: 30928903
Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.
Ross L, Hansen D, Proudman S, Khanna D, Herrick AL, Stevens W, Baron M, Nikpour M; Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Group. Ross L, et al. Among authors: khanna d. Arthritis Rheumatol. 2024 Nov;76(11):1635-1644. doi: 10.1002/art.42939. Epub 2024 Aug 26. Arthritis Rheumatol. 2024. PMID: 38937146
An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey).
Ingegnoli F, Ughi N, Dinsdale G, Orenti A, Boracchi P, Allanore Y, Foeldvari I, Sulli A, Cutolo M, Smith V, Herrick AL; EULAR Study Group on Microcirculation in RheumaticDiseases. Ingegnoli F, et al. Rheumatol Int. 2017 Nov;37(11):1879-1890. doi: 10.1007/s00296-017-3808-0. Epub 2017 Sep 11. Rheumatol Int. 2017. PMID: 28894946
789 results